Moderna (MRNA) Stock Surges on Personalized Cancer Vaccine Success: Should Investors Buy?

Key Takeaways

• Moderna shares surged more than 14% following successful Phase 3 results for intismeran autogene, its personalized cancer therapy developed with Merck
• Clinical data demonstrated that intismeran plus Keytruda extended recurrence-free survival in melanoma patients versus Keytruda monotherapy
• Barclays elevated its Moderna price target from $48 to $125; Wolfe Research shifted its rating from Underperform to Peer Perform
• Peak revenue projections reach $9.2B across four oncology indications, according to Wolfe analysts, prior to Merck’s share
• Shares have climbed 392% this year, raising concerns among some analysts that significant commercial potential is already reflected in valuations

Moderna shares traded at approximately $154.94 Tuesday afternoon, climbing nearly 12% during the session and ranking as the S&P 500’s strongest performer that day. The upward momentum follows last week’s sharp rally triggered by Phase 3 data, a subsequent pullback, and renewed buying interest.

Moderna, Inc., MRNA

The driving force behind the rally is promising late-stage trial data for intismeran autogene, a personalized mRNA-based cancer therapy created through collaboration with Merck. Study results revealed that combining intismeran with Merck’s checkpoint inhibitor Keytruda extended the period melanoma patients remained disease-free compared to treatment with Keytruda alone. This marks the first successful Phase 3 outcome for an mRNA-based cancer immunotherapy.

The clinical study enrolled 1,100 participants who received the investigational treatment following surgical removal of melanoma tumors. Intismeran is designed to target as many as 34 patient-specific neoantigens—abnormal proteins expressed on malignant cells that enable immune recognition and destruction of cancerous tissue. Every dose is customized through sequencing of the patient’s excised tumor to identify its distinctive genetic alterations.

Manufacturing the personalized vaccine requires approximately six weeks from initial tissue collection to final product delivery. During this production interval, patients can initiate Keytruda therapy while awaiting their individualized treatment.

Wall Street Reassesses Investment Outlook

Barclays analyst Eliana Merle increased her firm’s Moderna price objective to $125 from $48 while maintaining an Equal Weight stance. Her analysis suggests a favorable probability that intismeran will successfully navigate regulatory approval.

Wolfe Research shifted its position Tuesday, upgrading Moderna from Underperform to Peer Perform. Analyst Alexandria Hammond observed that investor confusion regarding cancer vaccine mechanisms may have amplified last week’s dramatic price movement.

BofA Securities and William Blair similarly upgraded their recommendations following the clinical announcement. Wolfe’s financial modeling estimates unadjusted peak revenue of $9.2B spanning four therapeutic areas—adjuvant melanoma, RCC, MIBC, and NSCLC—before accounting for Merck’s revenue allocation.

Leerink Partners anticipates intismeran could deliver annual revenue in the low single-digit billions by 2032. Merck’s internal forecasts suggest approximately $6 billion by 2035.

Market Cap Gains Raise Pricing Concerns

Moderna and Merck collectively added over $40 billion in combined market capitalization within a single trading session last Wednesday. Given that a $10 billion sales peak underpins roughly $40 billion in market value creation, some analysts question whether substantial appreciation remains available at current trading levels.

Intismeran’s effectiveness across additional cancer types remains unproven. Nine active trials are evaluating the therapy in various solid malignancies, including lung, kidney, and pancreatic cancers. While analysts generally interpret the melanoma results favorably for these ongoing studies, outcomes cannot be assumed.

Market observers project 2027 as a feasible commercial launch timeframe assuming interim data remains supportive. Moderna’s 52-week peak stands at $176.66.

Tuesday also saw Wolfe Research and Argus increase their Merck price targets, highlighting pipeline robustness. Merck continues searching for its next major revenue driver as Keytruda’s patent protection window narrows.